Epigenetic and Oncogenic Inhibitors Converge to Drive a Metabolic Catastrophe in Castration-Resistant Prostate Cancer

[The Journal of Clinical Investigation] Scientists showed that EZH2 inhibitors synergize with PI3K, AKT, or mTORC1 inhibitors to kill CRPC in vitro and promote tumor regression in vivo .